Cardiology update





Date

Meeting

Title

Total: 206

10/2013

Vascular 2013

Anti-VEGF Therapy: More Than Meets the Eye
Reviewed by: Michael Kutryk, MD,PhD, FRCPC

11/2011

AHA 2011

Emerging Oral Anticoagulation Options
in the Management of Acute Coronary Syndrome

Reviewed by: GORDON MOE, MD, FRCP(C), FACC

10/2011

2011 CCC

Understanding the Relationship Between Hypercholesterolemia and CKD – How is Kidney Disease Impacted by Dyslipidemia?
Reviewed by: GORDON MOE, MD, FRCP(C), FACC

08/2011

ESCC 2011

Optimizing the Care of Pulmonary Arterial Hypertension:
The Importance of Functional Class and the Specific Challenges of Eisenmenger Syndrome

Discussed by: GORDON MOE, MD, FRCP(C), FACC
Presented by: Nazzareno Galiè, MD; Marc Humbert , MD, PhD; Vallerie V. McLaughlin, MD; Gerhard P. Diller, MD; Maurice Beghetti, MD; and Michael A. Gatzoulis, MD

08/2011

ESCC 2011

Advancing Stroke Prevention in Atrial Fibrillation:
The Emerging Role of Factor Xa Inhibition

Discussed by: MILAN GUPTA, MD, FRCPC, FACC
Presented by: Keith Fox, MD; Jean-Yves Le Heuzey, MD; John W.A. Eikelboom, MD, MBBS; Christoph Bode, MD; and Graeme Hankey, MBBS, MD

04/2011

2011 World Congress of Nephrology

Reducing Cardiovascular Events in
Patients with Chronic Kidney Disease

Discussed by: GORDON MOE, MD, FRCP(C)
Originally presented by: Tonelli M, MD; Keane WF, MD; Baigent C, FFPH, FRCP; Shlipak M, MD; Tuttle KR, MD; Parving H-H, MD

08/2010

ESCC 2010

Management of Pulmonary Hypertension
Associated with Congenital Heart Disease

Discussed by: GORDON MOE, MD, FRCPC, FACC
Originally presented by: Mikael Dellborg, MD, PhD; Jean-Luc Vachiéry, MD; and Michael Gatzoulis, MD, PhD

11/2009

2009 Congress of the European Society of Cardiology

Clinical Efficacy and Safety of Otamixaban, an Intravenous, Selective Factor Xa Inhibitor for the Treatment of Non-ST-Elevation Acute Coronary Syndromes: Results of SEPIA-ACS1 TIMI 42
Discussed by: GORDON MOE, MD, FRCPC, DABIM
Originally presented by: Marc S. Sabatine, MD

10/2009

CCC

Meeting the Challenges in Atrial Fibrillation Management: New Treatments, New Opportunities
Discussed by: PAUL DORIAN, MD, FRCPC
Originally presented by: Denis Roy, MD, FRCPC; Stuart Connolly, MD, FRCPC; Paul Dorian, MD, FRCPC; and L. Brent Mitchell, MD, FRCPC

10/2009

Satellite Session at the 2009 Congress of the European Society of Cardiology

NYHA Functional Class II: An Achievable Goal for All Patients with Pulmonary Arterial Hypertension Receiving Treatment
Simon Gibbs, MD, Jean-Luc Vachiéry, MD, Nazzareno Galiè, MD, and Vallerie McLaughlin, MD
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by a poor prognosis with a median survival of ~2.8 years in patients with untreated idiopathic PAH, and
only 1 year for patients with untreated PAH associated with systemic sclerosis (scleroderma). The prevalence of PAH ranges from 15 to 50 patients per 1 million population; for
instance, in the United Kingdom the number of patients receiving treatment for PAH is 27 patients/million population.

09/2009

Satellite Symposium presentation at the 2008 Canadian Cardiovascular Congress

Glycemic control in diabetes: Does it matter?
KAMRAN AHMAD, MD, FRCPC
Although cardiovascular disease (CVD) eclipses many of the disabling and fatal complications of diabetes and diabetes management leads to a reduction in microvascular as well as
macrovascular complications, it may be incorrect to assume that effective management of diabetes will lead to a reduction in CV events in the same time frame as management of other modifiable CV risk factors, such as hypertension, lipids, and smoking.

08/2009

ESCC

New Perspectives in Long-term Anticoagulation: An Innovative Approach to Improve Patient Management
Discussed by: GORDON MOE, MD
Originally presented by: Ander T. Cohen, MBBS, MD; Jonathan L. Halperin, MD; Gilles Montalescot, MD, PhD; Marc Cohen, MD; and Philippe Gabriel Steg, MD

06/2009

SMHC

Targeted Cholesterol Reduction and Atherosclerosis: The Impact of Lower Targets for LDL Cholesterol on Atherosclerosis
in Patients with Diabetes

DAVID FITCHETT, MD and JUAN CARLOS MONGE, MD
Originally presented by: William James Howard, MD
Reduction of low-density lipoprotein cholesterol (LDL-C) is associated with improved cardiovascular (CV) outcomes in patients both at risk for and with established vascular disease. Guideline targets for cholesterol lowering have
steadily fallen; consequently, it has become more difficult to achieve the lower targets with statins alone.

03/2009

ACC

Effect of Rosuvastatin on Cardiovascular Outcomes in Patients on Chronic Hemodialysis: The AURORA Study
Discussed by: GORDON MOE, MD
Originally presented by: Bengt C. Fellström, MD, PhD


03/2009

ACC

Optimizing Patient Outcomes in Acute Heart Failure Syndrome: Strategies to Preserve Cardiorenal Function
Discussed by: GORDON MOE, MD
Originally presented by: Christopher M. O’Connor, MD, Michael M. Givertz, MD, Barrie M. Massie, MD, and Wilson Tang, MD

10/2008

CCC 2008

The Evolution of Stroke Prevention: Where are We Now? Where are We Going?
Discussed by: GORDON MOE, MD, FRCPC
Originally presented by: Pavel Hamet, MD; Christian Constance, MD; Philip Teal, MD; and Alexander Turpie, MD

10/2008

CSIM

Optimizing Therapeutic Strategies for Hypertensive Diabetics
By GORDON MOE, MD, FRCPC
Originally presented by: Finlay McAlister, MD; Sheldon Tobe, MD; and Ellen Burgess , MD

08/2008

ESCC

Survival Benefits of Aldosterone Blockade: Expanding the Standard of Care for Congestive Heart Failure Post-Myocardial Infarction
By GORDON MOE, MD, FRCPC
Originally presented by: Helmut Drexler, MD; Michel Komajda, MD; Allan Struthers, MD; Gerasimos Filipatos, MD; and Dirk van Veldhuisen, MD

03/2008

ACC

The ENHANCE Study: What Do We Know Now?
Reported by: GORDON MOE, MD
Originally presented by: John Kastelein, MD

03/2008

ACC

A Novel Way to Slow the Progression of Atherosclerosis: Inhibition of the Endocannabinoid Receptor
Reported by: DAVID FITCHETT, MD, FRCPC, FACC
Originally presented by: Steven E. Nissen, MD, and simultaneously published in the Journal of the American Medical Association

11/2007

AHA

Controlled Rosuvastatin Multinational Trial in
Heart Failure (CORONA): The Role of Statins in Patients with Heart Failure and Systolic Dysfunction

By JUAN CARLOS MONGE, MD, and GORDON MOE, MD
Originally presented by: Åke Hjalmarson, MD

10/2007

CCC

Getting Behind Traditional Targets to Achieve Optimal Cardiovascular Risk Reduction
By GORDON MOE, MD
Originally presented by: Lawrence A. Leiter, MD; Jean-Louis Chiasson, MD; and Richard Lewanczuk, MD

10/2007

CCC

The Clinical Roadmap to Acute Heart Failure:
Ascending to New Heights

By GORDON MOE, MD
Originally presented by: Paul W. Armstrong,MD; Michel White, MD; Peter Liu, MD; Jonathan Howlett, MD; and Justin Ezekowitz, MD

09/2007

ESCC

Prevention of Cardiovascular Events in Diabetic Patients:
The ADVANCE Study

By JUAN CARLOS MONGE, MD, FRCPC, FACC
Originally presented by: J Chalmers , MD; G Mancia, MD; S MacMahon, MD; N Poulter, MD

09/2007

ESCC

New Evidence in the Management of Cardiovascular Risk: The Place of Heart Rate
By MICHAEL R. FREEMAN, M.D.
Originally presented by: M Böhm, MD; K Fox, MD; G Heusch, MD; X Jouven, MD; J-C Tardif, MD; and A Hjalmarson. MD

09/2007

ESCC

Comprehensive Solutions for the Treatment of Atherosclerosis beyond Low-Density Lipoprotein Cholesterol
By DAVID FITCHETT, MD
Originally presented by: HB Brewer, Jr, MD; G Brown, MD; J Chapman, PhD; P Barter, MD; S Offermans, MD; John Paolini, MD, PhD; J Kastelein, MD, PhD

03/2007

ACC

Medical Crossfire – Managing Global Cardiometabolic Risk: How Can We Disrupt the Pathological Process?
By GORDON MOE, MD, FRCPC
Originally presented by: Christie M. Ballantyne, MD; Sidney C. Smith, Jr, MD; Deepak L. Bhatt, MD; Darren K. McGuire, MD; and Jorge Plutzky, MD

03/2007

ACC

Treating Anemia in the Setting of Heart Failure due to Systolic Left Ventricular Dysfunction: Controversies and Recent Data
By JONATHAN HOWLETT, MD
Originally presented by: James Young, MD

11/2006

AHA

The Obesity Epidemic:
A Focus on Global Cardiometabolic Risk

By GORDON W. MOE, M.D.
Originally presented by: Robert H. Eckel, MD; Linda Van Horn, MD; Linda Peterson, MD; Stephen Daniels, MD; and Jean-Pierre Despres, MD

10/2006

CCC

Connecting Prevention Strategies for Improving Cardiovascular Outcomes
By: Gordon Moe, MD
Originally presented by: Richard Lewanczuk, MD; Robert G. Josse, MD; Jacques de Champlain, MD;
and Ross Feldman, MD

10/2006

CCC

Heart Failure: Canadian Perspectives on the Management of Cardiorenal Syndrome and Acute Decompensated Heart Failure
By: DAVID FITCHETT, MD, and GORDON MOE, MD
Originally presented by: David Fitchett, MD; Jonathan Howlett, MD; and Peter Liu, MD; Adeera Levin, MD

09/2006

WCC

The Role of the Endocannabinoid System in Managing Cardiometabolic Risk (Part II): The Cardiovascular Consequences of Abdominal Adiposity and Cannabinoid-1 Receptor Blockade
By: Gordon Moe, MD
Originally presented by: Jean-Pierre Bassand, MD; Richard Nesto, MD; Vincenzo Di Marzo, PhD; and Philippe Gabriel Steg, MD

09/2006

WCC

Getting to the Heart of Alzheimer’s Disease: The Link Between Vascular Risk Factors, Cardiovascular Disease, and Alzheimer’s Dementia
By: Juan Carlos Monge, MD
Originally presented by: Kenneth Rockwood, MD; Xavier Girerd, MD; Ingmar Skoog, MD; Roy Jones, MD; and John Kastelein, MD

09/2006

WCC 2006

Where Have We Been? Where Are We Going?
A Forum on Statin Therapy and Clinical Trials

By: Juan Carlos Monge, MD
Originally presented by: David Waters, MD; Peter Ganz, MD; Pierre Amarenco, MD; and Terje Pedersen, MD

08/2006

WSCTS

Cardiac Surgical Management of Patients on Antiplatelet Agents
By LEE ERRETT, MD, FRCPC
Originally presented by: Lee Errett, MD; Linda Shore-Lesserson, MD

06/2006

XIV ISA

Atherosclerosis: From Lipids to Coronary Heart Disease
By: Juan Carlos Monge, MD, FRCPC
Originally presented by: Christie Ballantyne, MD, Herbert Schuster, MD, James Shepherd, MD, and John Kastelein, MD

05/2006

ASH

Combining Different Risk Interventions into a Single Formulation Contribute to Improved Cardiovascular Disease Risk Reduction: Preliminary Results of the JEWEL Program
By GORDON MOE, MD
Originally presented by: FDR Hobbs, MD; G. Gensini, MD; GBJ Mancini, MD; AJ Manolis, MD; B. Bauer, PhD; S Böhler, MD;
J. Genest, MD; R. Feldman, MD; P. Harvey, MD; TG Jenssen, MD; M. Metcalfe, MD; and P. Marques da Silva, MD

03/2006

ACC

The Role of the Endocannabinoid System in the
Management of Cardiometabolic Risk

By GORDON MOE, MD, FRCPC
Originally presented by: G Kunos, MD, PhD; RW Nesto, MD; SE Nissen, MD; L Van Gaal, MD; CM Ballantyne, MD; and SC Smith, Jr, MD

03/2006

ACC

The Role of Antiplatelet Agents in the Prevention of Atherothrombosis
By DAVID FITCHETT, M.D.
Originally presented by: Gabriel Steg, MD, and Deepak L Bhatt, MD

03/2006

AHA

Optimal Use of Fondaparinux as Antithrombotic
Therapy in Acute Coronary Syndromes – Integration
of Two Major Trials – OASIS-5 and OASIS-6

By MICHAEL R. FREEMAN, MD
Originally presented by: S. Yusuf, MB; SR Mehta, MD; CP Cannon, MD; JJ Popma, MD

11/2005

AHA

Insights from the Results of the Incremental Decrease in Endpoint through Aggressive Lipid Lowering (IDEAL) Trial
By GORDON W. MOE, M.D.
Originally presented by: Terje Pedersen, MD

10/2005

CCC

Novel Insights into the Renin Cascade and Heart Disease: Pursuing Excellence in Blood Pressure Control and Cardioprotection
By: Gordon Moe, MD, FRCPC
Originally presented by: Marc A. Pfeffer, MD; Arua M. Sharma, MD; Paul Ridker, MD

09/2005

ESCC

Acute Coronary Syndrome without ST-Elevation: What’s new?
By DAVID FITCHETT, MD
Originally presented by: J De Lemos, MD; FE Rademakers, MD; ML Simmoons, MD; DL Bhatt, MD; and SM Cobbe, MD

09/2005

ESCC

The Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Lowering Arm (ASCOT-BPLA) New Insights into the Prevention of Cardiovascular Events with the Newer versus the Older Antihypertensive Regimen
By GORDON W. MOE, M.D.
Originally presented by: Peter S. Sever, MD; Neil R. Poulter, MD; Björn Dahlöf, MD

03/2005

ACC

Optimizing Therapy in Acute Coronary Syndromes and Percutaneous Coronary Intervention
Reported and discussed by: Howard Leong-Poi, M.D.
Originally presented by: JE Tcheng, MD; CM Gibson, MD; NS Kleiman, MD; PA Gurbel, MD; ED Peterson, MD; RA Harrington, MD; SP Marso, MD

03/2005

ACC

Effect of Lowering LDL Cholesterol Substantially below Currently Recommended Levels in Patients with CHD: Results of the Treating to New Targets Study
Reported and discussed by: GORDON MOE, MD, FRCPC
Originally presented by: John C. LaRosa, M.D.

03/2005

ACC

Clopidogrel Use in Myocardial Infarction
Results of the CLARITY-TIMI 28 and COMMIT/CCS-2 Trials

Reported and discussed by: WARREN J. CANTOR, MD, FRCPC
Originally presented by: Marc S. Sabatine, M.D., and Zhenming Chen, M.D.

12/2004

SFHTA

Optimal Blood Pressure Control using Fixed-dose Combination Antihypertensive Therapy: Insights from a COmparative Study of efficacy of Irbesartan/hydrochlorothiazide with valsartan/hydrochlorothiazide using home blood pressure Monitoring in the treAtment of mild to moderate hypertension (COSIMA)
Discussed by: GORDON MOE, MD
Originally presented by: R. Asmar, MD; Nicolas Postel-Vinay, MD; Guillaume Bobrie, MD; and Alain Giacomino, MD

11/2004

AHA

ACE Inhibition in Patients with Coronary Artery Disease Results of the Trio of Trials, including the Late-Breaking Results of the Prevention of Events with Angiotensin-Converting Enzyme Inhibition (PEACE) Trial
Reported and discussed by: GORDON MOE, MD
Originally presented by: B. Pitt, MD; S. Yusuf, MD; WJ Remme, MD; FH Messerli, MD, and MA Pfeffer, MD.

11/2004

AHA

Quality Improvement in the Management of Acute Coronary Syndromes
Reported and discussed by: HOWARD LEONG-POI, M.D.
Originally presented by: MT Roe MD; EM Ohman MD; L Wallentin MD; SC Smith MD; HM Krumholz MD; G Ellrodt MD; ED Peterson MD; RM Califf MD

09/2004

ESCC

Acute Non-ST Elevation Coronary Syndromes: Open Issues
Reported and discussed by: DAVID FITCHETT, M.D.
Originally presented by: PW Armstrong, MD; A Betriu, MD; CW Hamm,MD; G Montalescot, MD; KAA Fox, MD; AWJ Van’t Hof, MD; AM Zeiher, MD

08/2004

ESCC

Effects of Long-acting Calcium Channel Blockade on
Cardiovascular Outcomes in Patients with Stable Angina
Pectoris: The ACTION (A Coronary disease Trial
Investigating Outcome with Nifedipine GITS) Trial

Reported and discussed by: GORDON MOE, MD
Originally presented by: Philip A. Poole-Wilson, MD

06/2004

EMH

The Importance of Prompt Blood Pressure Control to Target in High Risk Hypertensive Patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial
Reported and discussed by: GORDON MOE, MD
Originally presented by: Sverre E. Kjeldsen, MD, Stevo Julius, MD, and Michael Weber, MD

03/2004

ACC

Preventing Sudden Death: Have Prophylactic Implanted Defibrillators Finally Arrived?
A Report on the Preliminary Results of the SCD-HeFT Trial

Reported and discussed by: PAUL DORIAN, M.D.
Originally presented by: Dr. Gust Bardy, Principal Investigator for the SCD-HeFT Trial

03/2004

ACC

Treatment for ST-Elevation Myocardial Infarction An Update on Facilitated PCI trials and the Upcoming ACC/AHA STEMI Guidelines
Reported and discussed by: WARREN CANTOR, MD
Originally presented by: Elliott M. Antman, MD; Judith S. Hochman,MD; Eric R. Bates, MD; Michel Lemay, MD; and Joaquin Alonso, MD

03/2004

ACC

Defining the Role of Low-Molecular-Weight Heparin in the Era of Early Invasive Management of Acute Coronary Syndromes: Late-breaking results of the SYNERGY trial
Reported and discussed by: HOWARD LEONG-POI, M.D.
Originally presented by: KW Mahaffey, MD; JJ Ferguson, MD; SG Goodman, MD; EJ Topol, MD; RM Califf, MD

03/2004

ACC

What is the Latest and Greatest Antithrombotic Regimen for Unstable Cardiac Ischemic Syndrome?
Reported and discussed by: GORDON MOE, MD
Originally presented by: E.J. Topol, MD; S. Yusuf, MD; H.C. Herrmann, MD; Y.J. Woo, MD;
R.C. Becker, MD; and W.S. Weintrub, MD

03/2004

ACC

The Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE) Study
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: Donald Hunninghake, MD

03/2004

ACC

Stress Myocardial Perfusion Scintigraphy for Tracking Prognosis and Monitoring the Success of Anti-ischemic Therapies in Stable Survivors of AMI The INSPIRE Trial
Reported and discussed by: MICHAEL R. FREEMAN, M.D.
Originally presented by: John J Mahmarian, MD

11/2003

AHA

Treating Beyond Current Guidelines: Can Aggressive Lipid Lowering Result in Atherosclerosis Regression? Late-breaking results from the REVERSAL Study
Reported and discussed by: HOWARD LEONG-POI, M.D.
Originally presented by: Steven E. Nissen, M.D., and Allen J. Taylor, M.D.

11/2003

AHA

Optimal Inhibition of the Renin-angiotensin System in Patients with High-risk Myocardial Infarction: the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reported and discussed by: GORDON MOE, MD
Originally presented by: Marc A. Pfeffer, MD

11/2003

AHA

Low-Density Lipoprotein Oxidation Biomarkers Predict Cardiovascular Events in the PREVENT Study
Reported and discussed by: GORDON MOE, M.D.
Originally presented by: R. Preston Mason, MD

11/2003

AHA

Role of Low-Molecular-Weight Heparin in the Contemporary Management of Non-ST-Segment Elevation Acute Coronary Syndromes
Reported and discussed by: HOWARD LEONG-POI, M.D.
Originally presented by: Dean J. Kereiakes M.D., P. Gabriel Steg M.D., Keith Fox M.D., and Kim Eagle M.D.

11/2003

AHA

Oral Thrombin Inhibition in the Prophylaxis Against
Thromboembolism in Non-valvular Atrial Fibrillation
Late-breaking results of the Fifth Stroke Prevention using an Oral
Thrombin Inhibitor in Atrial Fibrillation (SPORTIF V) Study

Reported and discussed by: GORDON MOE, M.D.
Originally presented by: Jonathan L. Halperin, MD

11/2003

AHA

Role of Low-Molecular-Weight Heparin in the Contemporary Management of Non-ST-Segment Elevation Acute Coronary Syndromes
Reported and discussed by: HOWARD LEONG-POI, M.D.
Originally presented by: Dean J. Kereiakes M.D., P. Gabriel Steg M.D., Keith Fox M.D., and Kim Eagle M.D.

10/2003

CCC

Cholesterol and Vascular Biology
Reported and discussed by: DAVID FITCHETT, MD, FRCPC
Originally presented by: Todd Anderson, MD, and Subodh Verma, MD

08/2003

ESC

Comprehensive Management of Patients with Low and Preserved Ejection Fraction: The Candesartan in Heart failure – Assessment of Reduction in Mortality and morbidity (CHARM) Study
Reported and discussed by: GORDON MOE, MD
Originally presented by: C.B. Granger, MD; J.J.V. McMurray, MD; S. Yusuf, MD; and M.A. Pfeffer, MD

08/2003

ESC

ACE Inhibition and Cardiovascular Protection: The Impact of Emerging Data on Micro and Macrovascular Disease Management
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: G. Bakris, MD; H.C. Gerstein, MD; A.S. Hall, MD; P. Sleight, MD; J. Senges, MD; and S. Yusuf, MD

08/2003

ESCC

From Endothelin to Endothelin Receptor Antagonism: An Innovative Approach to Pulmonary Arterial Hypertension
Reported and discussed by: GORDON MOE, M.D. and DUNCAN STEWART, M.D.
Originally presented by: Vincent Richard, MD, Nazzareno Galie, MD, Olivier Sitbon, MD, Adam Torbicki, MD, Michael Gatzoulis, MD, and Lewis Rubin, MD

08/2003

ESCC

Prevention of Cardiac Events in Coronary Artery Disease with Perindopril
The EUROPA Study

Reported and discussed by: GORDON MOE, M.D.
Originally presented by: ME Bertrand, MD; JP Bassand, MD; R Ferrari, MD; ML Simoons, MD; KM Fox, MD; and WJ Remme, MD

05/2003

Symp. on NT-proBNP

New Frontiers in Cardiovascular Management Clinical Experiences and State-of-the-art Research on N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
Reported and discussed by: GORDON MOE, MD
Originally presented by: KB Swedberg, MD, C Hall, MD, OW Nielsen, MD, AHB Wu, MD, FS Apple, MD,
PO Collinson, MD, TA McDonagh, MD, AM Richards, MD, T Jernberg, MD, N Kucher, MD, CW Hamm, MD, et al.

03/2003

ACC

Practical Implications of Recent Hypertension Trials: Weighing the evidence
Reported and discussed by: GORDON MOE, MD
Originally presented by: Daniel Levy, MD; Richard H. Grimm, MD; Steven E. Nissen, MD; and Suzanne Oparil, MD

03/2003

ACC

Evidence-based strategies for the cardioprotective role of selective aldosterone blockade: Late-breaking results of the EPHESUS study
Reported and discussed by: GORDON MOE, MD
Originally presented by: Eugene Braunwald, MD, Faiez Zannad, MD, Bertram Pitt, MD, Milton Packer, MD, and Michael Weber, MD

03/2003

ACC

Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure: The COMPANION Trial
Reported and discussed by: PAUL DORIAN, M.D.
Originally presented by: Michael R. Bristow, MD, PhD, And M. Feldman, MD, PhD

03/2003

ACC

Across the Continuum of Cardiovascular Risk –
Evidence for Managing and Treating the Multiple Risk Factor Patient including late-breaking results of the ASCOT-LLA trial

Reported and discussed by: GORDON MOE, MD
Originally presented by: R. Preston Mason, PhD; Björn Dahlöf, MD; Peter Sever, MD; and Hans Wedel, MD

03/2003

ACC

Defining the Role of Bivalirudin in Percutaneous Coronary Intervention: Further Insights from REPLACE-2
Reported and discussed by: HOWARD LEONG-POI, MD
Originally presented by: A. Michael Lincoff M.D.; Neil S. Kleiman M.D.; Frederick Feit M.D.; David J. Cohen M.D.; and John A. Bittl M.D.

03/2003

CC

The Clinical Implications and Applications of Recent Trial Evidence from the ALLHAT Trial
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: Frans Leenen, MD, and Malcolm Arnold, MD

03/2003

Lake Louise, Alberta

Low-Molecular-Weight Heparin, Lytics, and Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: Shaun Goodman, M.D., Paul Armstrong, M.D., Christopher Granger, M.D., and Richard Gallo, M.D.

01/2003

Forum on ARAs

The cerebroprotective effects of AT1-receptor blockade
Reported and discussed by: JUAN CARLOS MONGE, MD
Edited by: GORDON MOE, MD
Originally presented by: Thomas Unger, MD, Peter Dominiak, MD, Peter Trenkwalder, MD, and Erling Tronvik, MD.

10/2002

CSS/CHS

Reaching Optimal Blood Pressure: What is the Role of Fixed-Dose Combinations?
Reported and discussed by: GORDON MOE, MD
Originally presented by: Kelly B. Zarnke, MD; Frans H.H. Leenan, MD; Martin G. Myers, MD; Norm Campbell, MD

10/2002

ACC & CCC

Preventing sudden death with prophylactic ICDs
Reported and discussed by: PAUL DORIAN, MD
A portion of the material was originally presented by: A. J. Moss, MD

10/2002

CCC

ACEI and ARB: Balancing the hope, hype, and evidence
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: J.C. Russell, MD; S. Verma, MD; E. Lonn, MD; T.J. Anderson, MD; P. Liu, MD

09/2002

HFSA & AHA

Anti-inflammatory Therapy in Heart Failure
Reported and discussed by: GORDON MOE, MD
Originally presented by: Milton Packer, MD; Doug Mann, MD; Eugene S. Chung, MD; and Guillermo Torre-Amione, MD

08/2002

ESC

Managing Chronic Heart Failure Improving LV Function and Mortality with Comprehensive Beta-Blockade
Reported and discussed by: GORDON MOE, M.D.
Originally presented by: W.J. Remme, MD, J.G.F. Cleland, MD, H. Krum, MD, and M. Packer, MD

08/2002

ESC

The Emerging Role of Angiotensin Receptor Blockers in Cardiovascular Protection: New Data, New Studies
Reported and discussed by: GORDON MOE, MD
Originally presented by: AP Maggioni, MD; KA Jamerson, MD; JJV McMurray, MD; R Latini, MD; JN Cohn, MD; SM Haffner, MD; D Hayoz, MD

08/2002

ESC

Smoking Cessation and Strategies in Clinical Practice
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: P. Hajek, MD, K.O. Fagerstrom, MD, and U. Keil, MD

05/2002

ISCP

Looking beyond Lipid-lowering
New Horizons of Treatment

Reported and discussed by: GORDON MOE, MD
Originally presented by: Jean Davignon, MD, Jules Lam, MD, Steven A. Grover, MD

05/2002

ASH

The PROGRESS Trial and the Prevention of Recurrent Stroke: Applying Results to Clinical Practice
Reported and discussed by:
GORDON MOE, MD
Originally presented by: John P. Chalmers, MD, PhD and Jan A. Staessen, MD, PhD

03/2002

ACC

Further Insights into the Therapeutic Role of Beta-Blockers in
Patients with Heart Failure: The Impact of COPERNICUS and BEST

Reported and discussed by:
GORDON MOE, MD
A Report on Abstracts Originally Presented by: Hugo A. Katus, MD, David J. Bradley, MD, Jean Rouleau, MD

03/2002

ACC

The Therapeutic Role of Vasopeptidase Inhibition
in Heart Failure – Late-breaking Results of the OVERTURE Trial

Reported and discussed by: GORDON MOE, MD, DUNCAN STEWART, MD
Originally presented by: Milton Packer, MD

03/2002

ACC & ASH

The Therapeutic Role of Vasopeptidase Inhibition in Hypertension – Results of the OCTAVE Study
Reported and discussed by: GORDON MOE, MD
Originally Presented by: John Kostis, MD, Michael Weber, MD, and Henry Black, MD

03/2002

ACC

Effects of Valsartan on Morbidity and Mortality in
Patients with Heart Failure not receiving ACE Inhibitors

Reported and discussed by:
JUAN CARLOS MONGE, M.D.
Originally presented by: Aldo P. Maggioni, MD, Florence, Italy.

11/2001

AHA

Recent Advances in GP IIb/IIIa Inhibition: The Clinical Implications
Reported and discussed by:
GORDON MOE, MD

Originally presented by: J. Conor O’Shea MD, David J. Cohen MD, Deepak L. Bhatt MD, Robert P. Giugliano MD, Donald E. Cutlip MD, Lisa K. Jennings PhD, Matthew T. Roe MD, and Eric D. Peterson MD

09/2001

ESC

Long-term therapy with clopidogrel in addition to aspirin in the management of patients with acute coronary syndromes undergoing percutaneous coronary intervention: The PCI CURE Study.
Reported and discussed by:
DAVID FITCHETT, MD
Originally presented by: Shamir Mehta MD

03/2001

ACC

Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events: The CURE trial
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: S. Yusuf, M.D., E. Braunwald, M.D., D. Holmes M.D., K. Fox, M.D., R. Califf, M.D.

03/2001

ACC

Low Molecular Weight Heparin: Management Strategies in Acute Coronary Syndromes
Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: RM Califf, MD, EJ Topol, MD, CP Cannon, MD, JJ Ferguson, MD, FJ Van de Werf, MD

03/2001

ACC

The Expanding Therapeutic Role of the Beta-Adrenergic Receptor Blockers in Patients with Left Ventricular Systolic Dysfunction: Results of the COPERNICUS and CAPRICORN Trials
Reported and discussed by:
GORDON MOE, MD
Originally presented by: Milton Packer, MD and Henry J. Dargie, MD

03/2001

ACC

Anti-anginal and Lipid-lowering effects of Chronic Oral Androgen Supplementation In Elderly Male Patients with Coronary Heart Disease.
Reported and discussed by:
JUAN CARLOS MONGE, MD
Originally presented by: Giuseppe M.C. Rosano, MD

11/2000

AHA

Does Combined Angiotensin Receptor Blockade and ACE Inhibition Improve Clinical Outcomes in Patients with Heart Failure? Results of the Valsartan Heart Failure Trial (Val-HeFT)
Reported and discussed by:
GORDON MOE, MD
Originally presented by: Jay N. Cohn, MD

11/2000

AHA

The Present and Future of Fibrinolytic Therapy for Acute Myocardial Infarction
Reported and discussed by:
SHAUN GOODMAN, MD
Originally presented by: Frans Van de Werf, MD, PhD, Paul W. Armstrong, MD, C. Michael Gibson, MD

11/2000

AHA

Do the different COX-2 specific inhibitors exert different effects on the cardiovascular system?
Reported and discussed by: LAWRENCE LEITER, MD
Originally presented by: William B. White, MD, FACP, Gerald A. Faich, MD, MPH, Andrew Whelton, MD, FACP, Daniel Levy, MD, FACC, Bertram Pitt, MD, Chairman

10/2000

CCC-AHA

Major issues for the cardiovascular high-risk patient: Rationale and evidence provided by HOPE
Reported and discussed by
DAVID FITCHETT, MD
Originally presented by: GR Dagenais, MD, S Yusuf, MD, E Lonn, MD, J Probstfield, MD, A Lamy, MD, CD Furberg, MD

10/2000

CCC

Calcium Channel Antagonists as Initial Hypertensive Drug Therapy - A Discussion of the NORDIL Trial
Reported and discussed by:
DAVID H. FITCHETT, MD
Originally presented by: L. Hansson, MD

08/2000

ISH

The Changing Paradigm of Hypertension Management:
Optimal Care of Patients with Multiple Risk Factors

Reported and discussed by:
GORDON MOE, MD. Originally presented by: L.E. Ramsay, MD, M. Epstein, MD, W.B. White, MD, E.L. Schiffrin, MD, A.B. Miller, MD

08/2000

ESC

Is ACE Inhibition the Standard of Care
for Management of Coronary Artery Disease?

Reported and discussed by:
DAVID FITCHETT, MD
Originally presented by: Victor Dzau, MD, Thomas Luscher, MD, Kenneth Bernstein, MD, Helmut Drexler, MD, Peter Libby, MD, Eva Lom, MD, and Wiek van Gist, MD

08/2000

ESC-HFSA

Carvedilol improves survival in patients with advanced heart failure: Results of the COPERNICUS study
Reported and discussed by:
GORDON MOE, MD
Originally presented by: Milton Packer, MD

06/2000

ESH

The INSIGHT Trial: New Evidence on Cardiovascular Protection
Reported and discussed by:
DAVID FITCHETT, MD. Originally presented by: B. Neal, MD, J. Gasowski, MD, L.M. Ruilope, MD, M.J. Brown, MD and G. Mancia, MD

05/2000

ASH

Targeting Blood Pressure Goals and End-Organ Protection: Advances in Renin-Angiotensin System Blockade
Adapted and discussed by:
JUAN CARLOS MONGE, MD. Originally presented by: Joel Neutel, MD, Domenic A. Sica, MD, Ernesto L. Schiffrin, MD, PhD, Matthew R. Weir, MD

03/2000

ACC

Vasopeptidase Inhibition and
Improved Cardiovascular Outcomes

Reported and discussed by:
DAVID H. FITCHETT, MD.

03/2000

ACC

The RALES Study: Importance of aldosterone antagonism in the management of congestive heart failure
Presented and discussed by:
STUART J. HUTCHISON, MD. Originally presented by: Gordon H. Williams, MD

03/2000

ACC

Statins and Drug Interactions:
Do they have an impact on health care resources?

Reported and discussed by:
DAVID FITCHETT, MD. Originally presented by: Michael Iskedjian, B Pharm, MSc, Thomas Einarson, PhD

01/2000

JANUS

New Antithrombotic Therapies in Cardiac Ischemic Syndromes
Reported and discussed by:
Shaun Goodman, M.D., M.Sc. Originally presented by: Jeffrey I. Weitz, MD, Paul W. Armstrong, MD, John A. Cairns, MD, Michael D. Ezekowitz, MD

11/1999

AHA

Vasopeptidase Inhibition (VPI): An important step towards improved hypertension control and CHF management
Reported and discussed by:
GORDON MOE, MD and DUNCAN STEWART, MD
Originally presented by: Henry Black, M.D., Michael Weber, M.D., John Burnett Jr, M.D., Giuseppe Mancia, M.D., J.L. Rouleau, M.D.

11/1999

AHA

The ELITE II study, a direct comparison
of angiotensin-converting enzyme inhibition
and angiotensin receptor blockade in heart failure

Reported and discussed by:
GORDON MOE, MD
Originally Presented by: PHILIP A. POOLE-WILSON AND BERTRAM PITT

11/1999

AHA

Is ACE inhibition the standard of care for management of CAD? Tissue mechanisms to impact clinical outcomes
Reported and discussed by:
JUAN CARLOS MONGE, MD. Originally presented by: Carl J. Pepine, MD, Helmut Drexler, MD, Kenneth E. Bernstein, MD,Eva Lonn, MD, John Deanfield, MD, Harold L. Lazar, MD

10/1999

CCS

Emerging therapeutic role of the angiotensin-converting enzyme inhibitors: Implications of the HOPE Study
Reported and discussed by:
GORDON MOE, MD

10/1999

CCS-NASPE

Treatment of Acute Ventricular Arrhythmias
Reported and discussed by:
PAUL DORIAN, MD

10/1999

CCS

The Role of Statins in Dyslipidemia: Making the Difference
Reported and discussed by:
ANATOLY LANGER, MD
Originally presented by: Jean Davignon, MD, François Charbonneau, MD, Murray Huff, MD, Lawrence Leiter, MD

09/1999

HFSA

Advances in the Treatment of End-Stage Heart Failure
Reported and discussed by:
GORDON W. MOE, MD
Originally presented by: Mihai Gheorghiade, MD, Arthur M. Feldman, MD, Michael R. Bristow, MD, Evan Loh, MD, and Michael A. Acker, MD

08/1999

ESC

Update on clinical trials: ACE inhibitors, vitamin E
and cardiovascular events, moxonidine, and
anti-thrombotic therapy in heart failure

Reported and discussed by:
Gordon Moe, MD

08/1999

ESC

Angiotensin II Type 1 Receptor Blockade –
Certainties, Probabilities, Possibilities

Reported and discussed by: GORDON MOE, MD
Originally presented by: I. JOHNSON, P.S. SEVER, J. McMURRAY, and V. DZAU

08/1999

ESC

How to implement best practice:
Addressing the difference between knowing and doing

Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: John Kasteleine, MD (Chair), Leif Erhardt, MD (Chair), Steven Grover, MD, David Wood, MD,
David Waters, MD, and Philip Barter, MD

08/1999

ESC

The Role of Irbesartan in Hypertension
and Diabetic Kidney Disease

Reported and discussed by: Shaun Goodman, MD, MSc
Originally presented by: Bernard Waeber, MD, Gustav Belz, MD, Arie Man in’t Veld, MD, Domenic Sica, MD, and Jerome Porush, MD

08/1999

ESC

Markers, Endothelial Function and Clinical Events:
Novel Aspects of Tissue ACE Inhibition

Reported and discussed by: DAVID FITCHETT, MD
Originally presented by: J. E. Deanfield MD, V. J. Dzau, MD, H. Drexler, MD, R Ferrari, MD, P. Ganz, MD, H. L. Lazar, MD, W. H. van Gilst, PhD

08/1999

ESC

A New Strategy in the Treatment of Heart Failure:
New Results from the MERIT-HF Trial

Reported and discussed by:
GORDON MOE, MD
Originally presented by: S. Gottlieb, MD, J. Wikstrand, MD, F. Waagstein, MD, M. Kendall, MD, B. Fagerberg, MD and S. Goldstein, MD

06/1999

EMH

Results of clinical trials: Implications for cardiovascular care
Reported and discussed:
GORDON MOE, MD
Originally presented by: JA STAESSEN, MD, F FORRETTE, MD, PW DE LEEUW, MD, TF LUSCHER, MD

06/1999

HEART FAILURE ’99

AT1 receptor blockade – New possibilities in heart failure
Reported and discussed by:
GORDON MOE, MD
Originally presented by: John McMurray, MD, Peter Meredith, MD, Jean Lucien Rouleau, MD, and Karl Swedberg, MD

05/1999

ASH

New Insights on Combination Therapy for Arterial Hypertension
Reported and discussed by: JUAN CARLOS MONGE, MD
Originally presented by: FH Messerli, MD, G Carruthers, MD, L. Corradi, MD

03/1999

ACC

Update on Clinical Trials
Presented and discussed by: ANATOLY LANGER, MD.

03/1999

ACC

Future Directions of Statin Therapy
Reported and discussed by: BETH ABRAMSON, M.D
Originally presented by: Antonio M. Gotto Jr, MD, Peter Libby, MD, Scott M. Grundy, MD, PhD,
Donald B. Hunninghake, MD, W. Virgil Brown, MD, Bertram Pitt, MD.

03/1999

ACC

Update on HMG-CoA reductase inhibitor therapy
Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: A.M. Keogh, MD, P.S. MacDonald, MD, C. Aboyoun, MD, J.A. Mundy, MD,
D. McCaffrey, MD, and P.M. Spratt, MD

03/1999

ACC

Inflammation, Ischemia, and Angiogenesis:
New Therapeutic Targets in Cardiovascular Disease

Reported and discussed by: SHAUN GOODMAN, MD, MSc
Originally presented by: Victor Dzau, MD, Paul Ridker, MD, MPH, Helmut Drexler, MD, Carl Pepine, MD, Jeffrey Isner, MD, and Akimi Uehata, MD

03/1999

ACC

New directions in thrombolytic therapy: The ASSENT II and InTime-II Trials
Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: Frans Van de Werf, MD and Karl-Ludwig Neuhaus

03/1999

ACC

The PREVENT Study: Renewed Interest in the Antiatherosclerotic Effects Of CCBs
Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: Robert P. Byington MD, John Chen MD, Curt D. Furberg, MD, Bertram Pitt, MD, Serge Lepage, MD

11/1998

AHA

Thrombolysis in Acute Myocardial Infarction:
Patency, Perfusion, and Prognosis

Reported and discussed by:
SHAUN GOODMAN, MD, MSc
Originally presented by: Steven E. Nissen, MD, Karl-Ludwig Neuhaus, MD, Eric J. Topol, MD, Elliott M. Antman, MD, Sorin Brener, MD

11/1998

AHA

Lowering of LDL cholesterol with statins: New insights
Reported and discussed by:
SHAUN GOODMAN, MD, MScOriginally presented by: Terje Pedersen, MD; Lemuel A. Moye, MD, PhD; Bertram Pitt, MD

11/1998

AHA

New Perspectives in Atherosclerosis Prevention
and Treatment

Reported and discussed by:
ANATOLY LANGER, MD
Presented by: J. Davignon, P. Libby, T.F.Lüscher

11/1998

AHA

Angiotensin II AT1 Receptor Blockers:
Are there differences that might affect outcome?

Reported and discussed by:
DAVID FITCHETT, MD
Originally presented by: Ernesto Schiffrin MD, PhD, Gustav Belz MD PhD, Matthew Weir MD, Edward Havranek MD, Michael Weber MD

11/1998

AHA

Functional effects of ACE inhibitors in the human vasculature
Reported and discussed by
DAVID FITCHETT, MD
Originally presented by: Victor Dzau, Paul Ridker, Helmut Drexler, Douglas Vaughan, Kenneth Bernstein, Wiek Van Gilst, Jeffrey Isner, and Ronald Crystal

11/1998

AHA

Omapatrilat: A novel vasopeptidase inhibitor for
the treatment of heart failure

Reported and discussed by:
GORDON MOE, MD and DUNCAN STEWART, MD
Originally presented by: H. Pouleur, MD, H. Ikram, MD, D. Synhorst, MD and J. Hanyok, Pharm.D.

11/1998

AHA

The role of AT1 receptors in target organ disease:
A functional perspective

Reported and discussed by
SHAUN GOODMAN, MD, MSc
Presented By Victor J. Dzau, MD, Andrew M. Allen, BSc, PhD, Edward D. Frohlich, MD, L. Gabriel Navar, PhD, And Suzanne Oparil, MD

10/1998

CCS

The Endothelium as a Modulator of Atherosclerotic Risk
Reported and discussed by: JUAN CARLOS MONGE, MD
Presented by: Todd Anderson, MD

10/1998

CCS

State of the art treatment of acute coronary syndromes
Reported and discussed by:
ANATOLY LANGER, MD
Presented by: Robert Califf, MD

08/1998

ESC

Low molecular weight heparins in the
management of acute coronary syndromes

Reported and discussed by:
SHAUN GOODMAN, MD
Originally presented by: Michel Bertrand, MD, Graham Turpie, MD, James Chesebro, MD, Werner Klein, MD, Stewart Hillis, MD

08/1998

ESC

Low molecular weight heparin in acute coronary syndromes: Preliminary results from the TIMI 11B Study
Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: Elliott Antman, MD

08/1998

ESC

The Role of Calcium Channel Blockers in Congestive Heart Failure
Reported and discussed by: SHAUN GOODMAN, MD
Presented by: William B. Kannel, MD, MPH, R. Preston Mason, PhD., John McMurray, MD, Milton Packer, MD

08/1998

ESC

Mechanisms of successful cardiovascular disease prevention
Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: B. M. Buckley, MD, J.W. Jukema, MD, J.W. Warnica, MD, E.T. Rapse, MD.

08/1998

ESC

Clinical Trial Hotlines: Preliminary Results from
the XXth Congress of the European Society of Cardiology

Heart failure studies (CIBIS-II and MACH-I)
reported by GORDON MOE, MD. CAD trials (BIP, GUSTO-III, TIMI IIB, and FRAX.I.S)
reported by SHAUN GOODMAN, MD
Originally presented by: Henry J. Dargie, MD, Uri Elkayan, MD

05/1998

ASH

Treating systolic hypertension in the elderly:
What therapeutic options are available?

Reported and discussed by:
MICHAEL R. FREEMAN, MD
Presented by Dr. Lisheng Liu and Dr. J. A. Staessen

03/1998

ACC

The Living Lining: The Endothelium as a Strategic Target
of Therapy for Cardiovascular Disease

Reported and discussed by:
JUAN CARLOS MONGE, MD
Originally presented by: Victor Dzau, MD, Michael Weber, MD,
Helmut Drexler, MD, Carl Pepine, MD, and Todd Anderson, MD

03/1998

ACC

The renin-angiotensin system, endothelial dysfunction, and vascular
reactivity: The role of angiotensin-converting enzyme inhibition

Reported and discussed by
SHAUN GOODMAN, MD
Originally presented by P. P. Van Geel, MD, M. Oostergra, MD, J.D. Blumenfeld, MD, and T. Anderson, MD

03/1998

ACC

Identifying the best practices for advanced heart failure:
Defining, debating, deciding

Reported and discussed by:
GORDON MOE, MD
Selected topics presented by: Kirk F. Adams, Jr., MD, Lynn Warner Stevenson, MD, Ileana L. Pina, MD, Barry M. Massie, MD, Michael S. Cuffe, MD, Maria R. Constanzo, MD, Robert M. Califf, MD

03/1998

ACC

Update on ACE inhibitors: The ATLAS and RESOLVD trials
Reported by and discussed by:
GORDON MOE, MD
Presented by Milton Packer, MD and members of the ATLAS Steering Committee, and S. Yusuf, MD and J.L. Rouleau, MD

03/1998

ACC

The Role of Angiotensin II AT1 Receptor Blockers
in Congestive Heart Failure and LVH

Reported and discussed by:
DUNCAN J. STEWART, MD
Originally presented by: M. Tonkon, MD, M. Tocchi, T. Kahan, MD and N. Vijay, MD

03/1998

ACC

NCEP Guidelines for cholesterol lowering: The clinical evidence
Reported and discussed by:
ANATOLY LANGER, MD
Originally presented by: Donald B. Hunninghake

11/1997

AHA

Whither ACLS? A Preliminary Report From The ARREST Trial
Reported and discussed by
PAUL DORIAN, MD
Based in part on a presentation by Peter Kudenchuk, MD

11/1997

AHA

Lipid Lowering Therapy in Primary and Secondary Prevention:
Insights from LIPID and WOSCOPS

Reported and discussed by:
SHAUN GOODMAN, MD
Originally presented by: Chris Packard, PhD, DSc, Andrew Tonkin, MD

11/1997

AHA

Antiplatelet Agents in Cardiovascular Disease
Reported and discussed by:
ANATOLY LANGER, MD
Presented by Valentin Fuster, MD, James T. Willerson, MD, Thomas F. Luscher, MD, Eric J. Topol, MD

11/1997

AHA

Angiotensin-Converting Enzyme Inhibition and
Endothelial Dysfunction: The Taming of the Hostile Endothelium

Reported and discussed by:
Shaun Goodman, MD
Presented by David Celermajer, MB, PhD, Nigel Benjamin, MD, Todd Anderson, MD, Victor Dzau, MD,
Burkhard Hornig, MD, and Helmut Drexler, MD

11/1997

AHA

Are Calcium Channel Blockers Safe Post-Myocardial Infarction?
The CAMI Experience

Reported and discussed by:
STUART HUTCHISON, MD
Presented by: P. Datta, MD, D.J. Stewart, MD, A. Langer, MD, S. G. Goodman, MD, A. Barr, MD, R. Davies, MD, R. Dupuis, MD,
J. Ferguson, MD, M. J. Gardner, MD, P. Savard, MD, B. A. Sussex, MD, M. Talajic, MD, W. Warnica, MD and J.L. Rouleau, MD

11/1997

AHA

Treatment of Hypertension:
Past Achievements and Current Challenges

Reported and discussed by:
JUAN CARLOS MONGE, MD.
Presented by: Stevo Julius, MD, Matthew R. Weir, MD, Victor J. Dzau, MD, Joel M. Neutel, MD, And Domenic A. Sica, MD

10/1997

CCS

Cardioprotection and Renin-angiotensin System Blockade
Reported and discussed by:
SHAUN GOODMAN, MD
Originally presented by: Arie J. Man In’t Veld, Md, PhD

09/1997

RCPSC

Prevention of Coronary Artery Disease: Myth or Reality?
Reported and discussed by:
DAVID FITCHETT, MD
Originally presented by: N Poulter, JM Flack, WB Weglicki, H Elliott

08/1997

ESC

Heart Failure: Are We Optimizing Patient Management?
Reported and discussed by:
JUAN CARLOS MONGE, MD
Originally presented by: M. Packer, MD, J. Cleland, MD, H. Dargie, MD, L. Ryden, MD, P. Poole-Wilson, MD

08/1997

ESC

The Role of Angiotensin-converting Enzyme (ACE) Inhibitors in
the Prevention and Treatment of Atherosclerosis: A Clinical Approach

Reported and discussed by:
SHAUN GOODMAN, MD
Originally presented by: S. Yusuf, E. Lonn, N. Sharpe, D. Vaughan, S. Ball, and J. Slany

08/1997

ESC

New Developments in Thrombolytic Therapy
Reported by:
SHAUN GOODMAN, MD
Originally presented by: R. Wilcox, MD; F. VandeWerf, MD; C. Cannon, MD; and A. Ross, MD

08/1997

ESC

Glycoprotein IIb/IIIa Receptor Blockade in Myocardial Infarction
Reported and discussed by:
ANATOLY LANGER, MD
Originally presented by: E.J. Topol, MD, M.L. Simoons, MD, J. Adgey, MD, D.J. Kereiakes, MD

08/1997

ESC

Towards Optimal Outcomes with Myocardial Reperfusion:
The GUSTO III Trial

Reported by:
SHAUN GOODMAN, MD
Originally presented by: C. Bode, MD; D. Ardissino, MD; A. Betriu, MD; R. G. Wilcox, MD; H. D. White, MD;
P. W. Armstrong, MD; E. M. Ohman, MD; and E. J. Topol, MD

08/1997

ESC

Multifactorial Approach to the Treatment
of Cardiovascular Disease

Reported by:
PAUL DORIAN, MD
Originally presented by: R. G. Josse, MD, M. Hanefield, MD, J. C. Fruchart, MD, J. W. Jukema, MD, T. F. Luscher, MD

08/1997

ESC

The Safety and Efficacy of Calcium Antagonists:
Data from STEPHY II and Other Trials

Reported by:
SHAUN GOODMAN, MD
Originally presented by: P. Trenkwalder, MD

08/1997

ESC

New Trends in Atherothrombosis Treatment
Reported and discussed by:
JUAN CARLOS MONGE, MD
Originally presented by: K. Schrör, MD, C. Prentice, MD, J.R. Hampton, MD, R.L. Haberl, MD

08/1997

ESC

Simplifying the Management of Patients with Hypertension
Reported and discussed by:
PAUL DORIAN, MD
Originally presented by: Daniel Levy, MD, Gareth Beevers, MD, Thomas Hedner, MD, Hamid Ikram, MD, H. Gavras, MD, Norman K. Hollenberg, MD, A. Zanchetti, MD, John D. Swales, MD

06/1997

ESH

Systolic Hypertension in the Elderly:
the Systolic Hypertension in Europe Trial (Syst-Eur)

Discussed by:
JUAN CARLOS MONGE, MD
Originally presented by: J. Staessen on behalf of the Syst-Eur Investigators

06/1997

ESH

What target blood pressure?
The Hypertension Optimal Treatment (HOT) study: an update

Reported and discussed by: JUAN CARLOS MONGE, MD
Originally presented by: L. Hansson, S. Julius, L.M. Ruilope, I. Wiklund, B. Waeber

06/1997

CPC

New Perspectives in the Treatment of Cardiovascular Disease
Discussed by:
SHAUN GOODMAN, MD
Originally presented by: E. Stein, MD, M. Gaziano, MD, J. Parker, MD, E. Schiffrin, MD, J. Staessen, MD

05/1997

WCHF

Role of Long-term Angiotensin-converting Enzyme Inhibition
Post-myocardial Infarction and the Effect on Fibrinolysis

Reported by:
GORDON W MOE, MD
Originally presented by: A.S. Hall, Leeds, UK, and D.E. Vaughan, Nashville, TN, USA

05/1997

FWHC

Endothelin-1:
A Prognostic Indicator in Patients with Heart Failure?

Reported by:
DUNCAN STEWART, MD

05/1997

ASH

New pharmacologic approaches
to the management of hypertension

Reported by:
ANATOLY LANGER, MD
Originally presented by: Hans Brunner, MD, Hubert G. Pouleur, MD, Julia A. Breyer, MD

05/1997

ASH

Hypertension and the Elderly
Reported by:
STUART HUTCHISON, MD
Originally presented by: W. Appelgate, MD, Edward Frolich, MD, C. Whelton, MD,
Stephen MacMahon, MD, H.J. Ward, Md, C.B. Toal, MD

03/1997

ACC

The Role Of Endothelial Dysfunction In Coronary Artery
Disease And Implications In Therapy

Originally presented by: PETER GANZ, MD

03/1997

ACC

Improved Outcome in Patients with Unstable Angina
Undergoing Coronary Angioplasty:
Additional Insights from the EPIC, EPILOG, and CAPTURE Trials

Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: A. Michael Lincoff, MD, Jaap Deckers, MD, and Peter Klootwijk, MD

03/1997

ACC

Early Angiotensin-converting Enzyme (ACE)
Inhibitor Therapy for Myocardial Infarction:
The Benefit of Lisinopril in the GISSI-III Trial

Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: Roberto Latini, MD, and Maria G. Franzosi, PhD

03/1997

ACC

Improving Outcome in Patients
Undergoing Coronary Intervention:
Final Results of the EPILOG Trial

Reported and discussed by: ANATOLY LANGER, MD
Originally presented by: A.M. Lincoff, MD

03/1997

ACC

Molecular Biology of Calcium Channels
in the Cardiovascular System

Reported and discussed by: JUAN CARLOS MONGE, MD
Originally presented by: Arnold M. Katz, MD, D.Med. (Hon)

03/1997

ACC

Novel L- and T-type Calcium Channel Blockers
in Cardiovascular Therapy

Reported and discussed by: JUAN CARLOS MONGE, MD
Originally presented by: Barry M. Massie, MD

03/1997

ACC

New and Different Angiotensin II-Receptor Blockers
Reported and discussed by:
DUNCAN STEWART, MD, and GORDON MOE, MD
Originally presented by: Michael Weber, MD, J.N. Cohn, MD,
Franz H. Messerli, MD, and George L. Bakris, MD

03/1997

ACC

Current Understanding of Pathophysiology and
Treatment of Single Vessel Coronary Artery Disease

Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: Bernard J. Gersh, MB, ChD, DPhiL, FRCP

11/1996

AHA

What Is the Optimal Dose of Angiotensin Converting
Enzyme Inhibitors in Patients with Left Ventricular Dysfunction?

Reported and discussed by: GORDON MOE, MD
Presented by : Robert E. Foster

11/1996

AHA

Felodipine as adjunctive therapy in failing hearts
improves left ventricular emptying

Reported and discussed by: STUART HUTCHISON, MD

11/1996

AHA

A Novel Antithrombotic Agent in the Treatment
of Cardiovascular Disease:
Final results from the TIMI 11a and ESSENCE trials

Reported and discussed by: SHAUN GOODMAN, MD

10/1996

CCS

Endothelin and Endothelin Antagonists:
Treatment of CHF

Reported and discussed by: STUART HUTCHISON, MD

10/1996

CCS

Anti-anginal Drug Therapy in Stable Angina
The Need for Long-Term Outcome Studies

Reported and discussed by: SHAUN GOODMAN, MD

10/1996

CCS

Microalbuminuria and Cardiovascular Complications:
Is microalbuminuria the best marker for endothelial dysfunction?

Reported and discussed by: PAUL DORIAN, MD
Adapted from a lecture by: Dr. Norman K. Hollenberg

08/1996

ESC

Improving the Outcome in Patients with Unstable Refractory
Angina Undergoing PTCA: EPIC, EPILOG and the CAPTURE trials

Reported and discussed by: ANATOLY LANGER, MD

08/1996

ESC

An Exploration of Present and Future Applications
of Glycoprotein IIb/IIIa Inhibitors

Reported and discussed by: ANATOLY LANGER, MD

08/1996

ESC

Amiodarone: New Prophylactic Indications for an Old Drug?
Reported and discussed by: PAUL DORIAN, MD
Presented by: D.G. Julian, MD; J.A. Cairns, MD; E. Aliot, MD; S. Hohnloser, MD

08/1996

ESC

Secondary Prophylaxis with Simvastatin and Lovastatin:
Additional Insights from the XVIIIth Congress of the European Society of Cardiology

Reported and discussed by: SHAUN GOODMAN, MD

08/1996

ESC

Risk Factor Modification in Coronary Heart Disease:
Insights from the XVIIIth Congress of the European Society of Cardiology

Reported and discussed by: SHAUN GOODMAN, MD

08/1996

ESC

Role of heart rate lowering calcium antagonists
in post MI secondary prevention:
hypertension, non-Q wave MI, adjunctive therapy post thrombolysis

Reported and discussed by: ANATOLY LANGER, MD
Presented by: William E. Boden, MD

08/1996

ESC

Heart Rate Lowering Calcium Antagonists
in Cardiovascular Disease Management

Reported and discussed by: ANATOLY LANGER, MD

08/1996

ESC

Heart rate and cardiovascular mortality in hypertension:
Treatment strategies with heart rate lowering calcium antagonists

Reported and discussed by: ANATOLY LANGER, MD

05/1996

ASH

Safety of antihypertensive therapies:
A series of interactive panels (Part II) – Controversies in hypertension

Reported and discussed by: JUAN CARLOS MONGE,MD
Presented by: Barry J . M Aterson, MD, MBA, William B. Applegate, MD, Matthew R. Weir, MD, George L. Bakris, MD

05/1996

NASPE

A new indication for implantable defibrillators?
A discussion of the MADIT trial

Reported and discussed by: ALAN BAROLET, MD and PAUL DORIAN, MD
Presented by: Arthur J. Moss, MD for the MADIT Investigators

03/1996

ACC

The Safety and Efficacy of Heart Rate Lowering Calcium
Channel Blockers Revisited

Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: William E. Boden, MD

03/1996

ACC

Update on the calcium antagonist controversy:
the Furberg meta-analysis revisited

Reported and discussed by: SHAUN GOODMAN, MD
Originally presented by: Franz Messerli, MD

11/1995

AHA

Titration of Angiotension Converting Enzyme
Inhibition in Acute Anterior Infarction:
The Healing and Early Afterload Reducing Therapy (HEART) Study.

Reported and discussed by: GORDON W. MOE, MD
Originally presented by: Marc A. Pfeffer, MD

Total: 206